Quick Notes: July 2, 2020

  • Quantel Medical acquired Ellex, through the financial holding company Lumibird Medical. The purchase includes the Ellex brand name, its R&D and production site based in Adelaide and its subsidiaries based in Australia, Japan, the United States, France and Germany. The acquisition includes Ellex’s laser and ultrasound technology solutions, with the exception of the 2RT and iTrack. 

  • Visual Clinic, developers of a patient flow and operational productivity solution for eye care clinics, launched its new Safe Visits application. The software module provides ophthalmology and optometry practices with a streamlined care process designed to safely and efficiently guide patients and staff through appointments in the COVID-19 environment. For more information, visit

  • DORC launched a new range of EVA EquiPhaco needles and sleeves, designed for increased ultrasound efficiency, improved anterior chamber stability and easier sleeve positioning. Key enhancements in this line include optimized irrigation/aspiration balance; up to 45% larger tip diameter, with deeper inner steps in the flare; and a 1.1-m longer tip for further reach into the eye. 

  • OcuBlink, a developer of eye models for ophthalmic-related testing, introduced the first synthetic eyeball for augmented and virtual reality validation applications. The product is being piloted by AdHawk Microsystems to calibrate eye tracking in advanced AR/VR systems for medical and consumer electronics applications. AdHawk produces custom, wafer-scale silicon devices to accelerate the proliferation of eye tracking in a broad range of devices.

  • The American Diabetes Association, in partnership with VSP Vision Care and Regeneron, are hosting a media event to celebrate Healthy Vision Month. The event will include panel conversations among experts within the diabetes and eye health space with the goal of raising awareness for the impact of diabetes-related eye disease and vision loss. The date of the event is Friday, July 31, from 2 p.m. to 3:30 p.m. An invitation and registration link will follow at a later time. 
  • Allergan, an AbbVie company, and Molecular Partners announced that the FDA issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigational therapy for patients with neovascular (wet) AMD. The letter indicates that the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL results in an unfavorable benefit-risk ratio in the treatment of wet AMD. 
    According to Michael R. Robinson, MD, vice president, global therapeutic area head, ophthalmology, AbbVie, “We are committed to working with the FDA to determine the appropriate next steps for Abicipar pegol.”

  • Bio-Tissue announced the results of a retrospective study of patients with acute Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). The study found that 87% of the eyes treated with Bio-Tissue’s Prokera or AmnioGraft had vision maintained at 20/40 or better, and corneal blindness, a common complication of SJS/TEN, was prevented.
  • Epipole, a Scottish company specializing in video retinal imaging, secured $1.9 million in new funding to prepare for its introduction to the U.S. ophthalmic imaging market. Epipole also announced the appointment of Ian Stevens as chairman. Epipole’s patented technology enables clinicians to scan the retina using real-time video and then extract images for further examination. 
Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here